| Summary: | Submitted by Jorge Silva (jorgelmsilva@ufrrj.br) on 2017-09-12T18:24:02Z
No. of bitstreams: 1
2016 - Larissa Henriques Evangelista Castro.pdf: 3738174 bytes, checksum: 04e651a55fa9b4054c2810389592be67 (MD5) === Made available in DSpace on 2017-09-12T18:24:02Z (GMT). No. of bitstreams: 1
2016 - Larissa Henriques Evangelista Castro.pdf: 3738174 bytes, checksum: 04e651a55fa9b4054c2810389592be67 (MD5)
Previous issue date: 2016-12-02 === CAPES === CNPq === FAPERJ === Trypanosoma cruzi is the parasite that causes american trypanosomiasis (or Chagas disease), a neglected tropical disease previously restricted to South and Central Americas and Mexico, but now with several cases around the world. Currently in Brazil, the treatment of Chagas disease is done, only using benznidazole, which is not effective for the disease?s chronic phase and causes aggressive side effects, which explains the necessity of researches to find novel anti-Chagas compounds. A strategy adopted for the development of bioactive compounds against T. cruzi consists on the inhibition of the sterol 14?-demethylase enzyme (CYP51), which is essential for the parasite?s cellular membrane integrity. The inhibition can be achieved by a complexation of heterocyclic ring-containing compounds with the iron atom of heme group, present on CYP51. Thus, molecular modeling techniques were used on this study to analyze the interaction of a heterocyclic compounds (with known activity) with T. cruzi CYP51 in order to obtain the necessary information to construct an effective model for the theoretical activity prediction of these and also novel compounds. The proposed model presented a good multiple correlation coefficient (r? = 0.84) with the terms used to its construction. The model was used to help the design of novel piperine derivatives with a triazole ring, that presented promising theorical activities against T. cruzi CYP51, calculated by the model. The most promising compounds were selected and synthesized with the purpose of being tested in vitro and in vivo against T. cruzi. === O Trypanosoma cruzi ? o parasito causador da tripanossom?ase americana (Doen?a de Chagas), uma doen?a tropical negligenciada antes restrita ? Am?rica do Sul, Am?rica Central e M?xico, mas que vem apresentando um n?mero cada vez maior de casos no mundo. Atualmente, o tratamento da Doen?a de Chagas no Brasil ? limitado ao uso do f?rmaco benzonidazol, que ? pouco eficaz para a fase cr?nica da doen?a e causa efeitos colaterais agressivos, o que torna a pesquisa por novos f?rmacos imprescind?vel. Uma estrat?gia adotada para o desenvolvimento de compostos bioativos contra T. cruzi consiste na inibi??o de uma enzima essencial para a integridade da membrana celular do parasito, a enzima esterol 14?-desmetilase (CYP51), causada pela coordena??o de compostos contendo an?is heteroc?clicos com o ?tomo de ferro do grupo heme presente na enzima, fundamental para a atividade. Dessa maneira, foram utilizadas nesse estudo t?cnicas de modelagem molecular, incluindo docagem molecular e c?lculos qu?nticos semi-emp?ricos, para analisar a intera??o de uma s?rie de compostos heteroc?clicos de atividade conhecida sobre a CYP51 do T. cruzi e com isso se obter informa??es necess?rias para a constru??o de um modelo efetivo para a previs?o te?rica da atividade destes compostos. O modelo proposto apresentou um bom coeficiente de correla??o m?ltipla com os termos utilizados para sua constru??o, com um r?=0,84. Esse modelo foi utilizado para o planejamento de novos triaz?is derivados da piperina, com atividade te?rica calculada promissora contra a CYP51 de T. cruzi. Alguns dos melhores compostos foram selecionados e sintetizados neste projeto, com a proposta de serem avaliados em testes in vitro e in vivo contra a doen?a de Chagas.
|
|---|
